Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Humacyte, Inc.HUMA · Entity 6478 | Chief Regulatory Officer | January 21, 2025 | January 23, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Humacyte, Inc.
Report date January 21, 2025 · Filed January 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.56 · Expires 2035-01-21 | Direct | 283,101 |
Reported balance
After 2025-01-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-01-21 · Grant · Acquired 283,101 · Balance 283,101 F1: The first 25% of the option becomes exercisable on January 21, 2026, after which 1/48 of the option will become exercisable on the 21st of each month through January 21, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: The first 25% of the option becomes exercisable on January 21, 2026, after which 1/48 of the option will become exercisable on the 21st of each month through January 21, 2029.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 21, 2025 Filed Jan 23, 2025 21:34 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 283,101 | $0.00 Strike: $4.56 | $0.00 |
DisclosureSEC source: 0001818382-25-000019 · wk-form4_1737668079.xml · derivative · entry 1 Cao Yang · CIK 0001946538 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 283,101 Underlying: Common Stock · 283,101 shares Expires 2035-01-21 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on January 21, 2026, after which 1/48 of the option will become exercisable on the 21st of each month through January 21, 2029. Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 21:09 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 210,000 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001818382-23-000194 · wk-form4_1702415388.xml · derivative · entry 1 Cao Yang · CIK 0001946538 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,000 Underlying: Common Stock · 210,000 shares Expires 2033-12-08 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on December 8, 2024, after which 1/48 of the option will become exercisable on the 8th of each month through December 8, 2027. Read SEC document |
| September 19, 2022 Filed Sep 20, 2022 20:09 UTC | Humacyte, Inc. HUMA · Entity 6478 | GrantStock Options (right to buy) · Derivative | 145,000 | $0.00 Strike: $3.73 | $0.00 |
DisclosureSEC source: 0001818382-22-000174 · wf-form4_166370457260068.xml · derivative · entry 1 Cao Yang · CIK 0001946538 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 145,000 shares Expires 2032-09-19 F1 · derivative.exercise_date: The first 25% of the option becomes exercisable on September 19, 2023, after which 1/48 of the option will become exercisable on the 19th of each month through September 19, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.